{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:25:14Z","timestamp":1791901514744,"version":"4.3.4"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Genes that participate in the absorption, distribution, metabolism, excretion (ADME) processes occupy a central role in pharmacokinetics. Meanwhile, variability in clinical outcomes and responses to treatment is notable in bladder cancer (BLCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our study utilized expansive datasets from TCGA and the GEO to explore prognostic factors in bladder cancer. Utilizing both univariate Cox regression and the lasso regression techniques, we identified ADME genes critical for patient outcomes. Utilizing genes identified in our study, a model for assessing risk was constructed. The evaluation of this model's predictive precision was conducted using Kaplan\u2013Meier survival curves and assessments based on ROC curves. Furthermore, we devised a predictive nomogram, offering a straightforward visualization of crucial prognostic indicators. To explore the potential factors mediating the differences in outcomes between high and low risk groups, we performed comprehensive analyses including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG)-based enrichment analyses, immune infiltration variations, somatic mutation landscapes, and pharmacological sensitivity response assessment etc. Immediately following this, we selected core genes based on the PPI network and explored the prognostic potential of the core genes as well as immune modulation, and pathway activation. And the differential expression was verified by immunohistochemistry and qRT-PCR. Finally we explored the potential of the core genes as pan-cancer biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our efforts culminated in the establishment of a validated 17-gene ADME-centered risk prediction model, displaying remarkable predictive accuracy for BLCA prognosis. Through separate cox regression analyses, the importance of the model\u2019s risk score in forecasting BLCA outcomes was substantiated. Furthermore, a novel nomogram incorporating clinical variables alongside the risk score was introduced. Comprehensive studies established a strong correlation between the risk score and several key indicators: patterns of immune cell infiltration, reactions to immunotherapy, landscape of somatic mutation and profiles of drug sensitivity. We screened the core prognostic gene CYP2C8, explored its role in tumor bioregulation and validated its upregulated expression in bladder cancer. Furthermore, we found that it can serve as a reliable biomarker for pan-cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The risk assessment model formulated in our research stands as a formidable instrument for forecasting BLCA prognosis, while also providing insights into the disease's progression mechanisms and guiding clinical decision-making strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-025-00409-4","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:02:06Z","timestamp":1742371326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["ADME gene-driven prognostic model for bladder cancer: a breakthrough in predicting survival and personalized treatment"],"prefix":"10.1186","volume":"162","author":[{"given":"Haojie","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"3","key":"409_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"409_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s10654-016-0138-6","volume":"31","author":"AH Al-Zalabani","year":"2016","unstructured":"Al-Zalabani AH, Stewart KF, Wesselius A, Schols AM, Zeegers MP. Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses. Eur J Epidemiol. 2016;31(9):811\u201351. https:\/\/doi.org\/10.1007\/s10654-016-0138-6.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"409_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/fon-2017-0346","volume":"14","author":"A Phelan","year":"2018","unstructured":"Phelan A, Lopez-Beltran A, Montironi R, Zhang S, Raspollini MR, Cheng M, Kaimakliotis HZ, Koch MO, Cheng L. Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. Future Oncol. 2018;14(3):277\u201390. https:\/\/doi.org\/10.2217\/fon-2017-0346.","journal-title":"Future Oncol"},{"issue":"3","key":"409_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/ije\/dyw044","volume":"45","author":"FH van Osch","year":"2016","unstructured":"van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol. 2016;45(3):857\u201370. https:\/\/doi.org\/10.1093\/ije\/dyw044.","journal-title":"Int J Epidemiol"},{"issue":"9","key":"409_CR5","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaoncol.2015.3209","volume":"1","author":"MG Cumberbatch","year":"2015","unstructured":"Cumberbatch MG, Cox A, Teare D, Catto JW. Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2015;1(9):1282\u201390. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3209. Erratum in: JAMA Oncol. 2015 Dec;1(9):1224. https:\/\/doi.org\/10.1001\/jamaoncol.2015.5120.","journal-title":"JAMA Oncol"},{"issue":"1","key":"409_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"409_CR7","doi-asserted-by":"publisher","first-page":"175883592110473","DOI":"10.1177\/17588359211047352","volume":"13","author":"C Stecca","year":"2021","unstructured":"Stecca C, Abdeljalil O, Sridhar SS. Metastatic Urothelial Cancer: a rapidly changing treatment landscape. Ther Adv Med Oncol. 2021;13:17588359211047352. https:\/\/doi.org\/10.1177\/17588359211047352.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"409_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2217\/imt-2020-0128","volume":"13","author":"R Tambaro","year":"2021","unstructured":"Tambaro R, Napoli MD, Pisano C, Cecere SC, Attademo L, Rossetti S, Feroce F, Setola S, Califano D, Russo D, Spina A, Perdon\u00e0 S, Izzo A, Pignata S. From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer. Immunotherapy. 2021;13(1):67\u201377. https:\/\/doi.org\/10.2217\/imt-2020-0128.","journal-title":"Immunotherapy"},{"key":"409_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286\u2013287","author":"D Sonkin","year":"2024","unstructured":"Sonkin D, Thomas A, Teicher BA. Cancer treatments: Past, present, and future. Cancer Genet. 2024;286\u2013287:18\u201324. https:\/\/doi.org\/10.1016\/j.cancergen.2024.06.002.","journal-title":"Cancer Genet"},{"key":"409_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2015.03.014","volume":"86","author":"L Tao","year":"2015","unstructured":"Tao L, Zhang P, Qin C, Chen SY, Zhang C, Chen Z, Zhu F, Yang SY, Wei YQ, Chen YZ. Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools. Adv Drug Deliv Rev. 2015;86:83\u2013100. https:\/\/doi.org\/10.1016\/j.addr.2015.03.014.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"409_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd3367","volume":"10","author":"MP Gleeson","year":"2011","unstructured":"Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov. 2011;10(3):197\u2013208. https:\/\/doi.org\/10.1038\/nrd3367.","journal-title":"Nat Rev Drug Discov"},{"key":"409_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fgene.2019.00007","volume":"10","author":"K Klein","year":"2019","unstructured":"Klein K, Tremmel R, Winter S, Fehr S, Battke F, Scheurenbrand T, Schaeffeler E, Biskup S, Schwab M, Zanger UM. A New Panel-Based Next-Generation Sequencing Method for ADME Genes Reveals Novel Associations of Common and Rare Variants With Expression in a Human Liver Cohort. Front Genet. 2019;10:7. https:\/\/doi.org\/10.3389\/fgene.2019.00007.","journal-title":"Front Genet"},{"issue":"3","key":"409_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1124\/jpet.118.255018","volume":"368","author":"DG Hu","year":"2019","unstructured":"Hu DG, Marri S, McKinnon RA, Mackenzie PI, Meech R. Deregulation of the Genes that Are Involved in Drug Absorption, Distribution, Metabolism, and Excretion in Hepatocellular Carcinoma. J Pharmacol Exp Ther. 2019;368(3):363\u201381. https:\/\/doi.org\/10.1124\/jpet.118.255018.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"409_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/FPC.0000000000000260","volume":"27","author":"DH Hovelson","year":"2017","unstructured":"Hovelson DH, Xue Z, Zawistowski M, Ehm MG, Harris EC, Stocker SL, Gross AS, Jang IJ, Ieiri I, Lee JE, Cardon LR, Chissoe SL, Abecasis G, Nelson MR. Characterization of ADME gene variation in 21 populations by exome sequencing. Pharmacogenet Genomics. 2017;27(3):89\u2013100. https:\/\/doi.org\/10.1097\/FPC.0000000000000260.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"409_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/jhg.2015.115","volume":"61","author":"J Jittikoon","year":"2016","unstructured":"Jittikoon J, Mahasirimongkol S, Charoenyingwattana A, Chaikledkaew U, Tragulpiankit P, Mangmool S, Inunchot W, Somboonyosdes C, Wichukchinda N, Sawanpanyalert P, He Y, McLeod HL, Chantratita W. Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. J Hum Genet. 2016;61(2):119\u201327. https:\/\/doi.org\/10.1038\/jhg.2015.115.","journal-title":"J Hum Genet"},{"issue":"4","key":"409_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/ht7040040","volume":"7","author":"M Arbitrio","year":"2018","unstructured":"Arbitrio M, Di Martino MT, Scionti F, Barbieri V, Pensabene L, Tagliaferri P. Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives. High Throughput. 2018;7(4):40. https:\/\/doi.org\/10.3390\/ht7040040.","journal-title":"High Throughput"},{"issue":"10","key":"409_CR17","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/carcin\/bgn163","volume":"29","author":"JD Figueroa","year":"2008","unstructured":"Figueroa JD, Malats N, Garc\u00eda-Closas M, et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis. 2008;29(10):1955\u201362. https:\/\/doi.org\/10.1093\/carcin\/bgn163.","journal-title":"Carcinogenesis."},{"issue":"5","key":"409_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/carcin\/bgn071","volume":"29","author":"CY Liu","year":"2008","unstructured":"Liu CY, Hsu YH, Pan PC, Wu MT, Ho CK, Su L, Xu X, Li Y, Christiani DC, Kaohsiung Leukemia Research Group. Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia. Carcinogenesis. 2008;29(5):984\u201390. https:\/\/doi.org\/10.1093\/carcin\/bgn071.","journal-title":"Carcinogenesis."},{"issue":"1","key":"409_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12935-023-03084-5","volume":"23","author":"K Rehman","year":"2023","unstructured":"Rehman K, Iqbal Z, Zhiqin D, Ayub H, Saba N, Khan MA, Yujie L, Duan L. Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer. Cancer Cell Int. 2023;23(1):247. https:\/\/doi.org\/10.1186\/s12935-023-03084-5.","journal-title":"Cancer Cell Int"},{"issue":"22","key":"409_CR20","doi-asserted-by":"publisher","first-page":"12283","DOI":"10.3390\/ijms252212283","volume":"25","author":"K T\u0119cza","year":"2024","unstructured":"T\u0119cza K, Kalinowska-Herok M, Rusinek D, Zajkowicz A, Pfeifer A, Oczko-Wojciechowska M, Pamu\u0142a-Pi\u0142at J. Are the Common Genetic 3\u2019UTR Variants in ADME Genes Playing a Role in Tolerance of Breast Cancer Chemotherapy? Int J Mol Sci. 2024;25(22):12283. https:\/\/doi.org\/10.3390\/ijms252212283.","journal-title":"Int J Mol Sci"},{"issue":"39","key":"409_CR21","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.2174\/0929867323666161024154457","volume":"23","author":"M Drozdzik","year":"2016","unstructured":"Drozdzik M, Oswald S. Expression and Regulation of Drug Transporters and Metabolizing Enzymes in the Human Gastrointestinal Tract. Curr Med Chem. 2016;23(39):4468\u201389. https:\/\/doi.org\/10.2174\/0929867323666161024154457.","journal-title":"Curr Med Chem"},{"issue":"5","key":"409_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/cpt.343","volume":"99","author":"P Fisel","year":"2016","unstructured":"Fisel P, Schaeffeler E, Schwab M. DNA Methylation of ADME Genes. Clin Pharmacol Ther. 2016;99(5):512\u201327. https:\/\/doi.org\/10.1002\/cpt.343.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"409_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jfda.2018.11.005","volume":"27","author":"KC Wu","year":"2019","unstructured":"Wu KC, Lin CJ. The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders. J Food Drug Anal. 2019;27(1):48\u201359. https:\/\/doi.org\/10.1016\/j.jfda.2018.11.005.","journal-title":"J Food Drug Anal"},{"issue":"1","key":"409_CR24","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/s41598-024-84018-7","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang H, Li F, Wang Q, Guo X, Chen X, Zou X, Yuan J. Identifying ADME-related gene signature for immune landscape and prognosis in KIRC by single-cell and spatial transcriptome analysis. Sci Rep. 2025;15(1):1294. https:\/\/doi.org\/10.1038\/s41598-024-84018-7.","journal-title":"Sci Rep"},{"issue":"1","key":"409_CR25","doi-asserted-by":"publisher","first-page":"16834","DOI":"10.1038\/s41598-024-67516-6","volume":"14","author":"H Zhang","year":"2024","unstructured":"Zhang H, Huang W, Chen M, Liu Y, Yan B, Mou S, Jiang W, Mei H. Research on molecular characteristics of ADME-related genes in kidney renal clear cell carcinoma. Sci Rep. 2024;14(1):16834. https:\/\/doi.org\/10.1038\/s41598-024-67516-6.","journal-title":"Sci Rep"},{"issue":"11","key":"409_CR26","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.3390\/cancers12113369","volume":"12","author":"DG Hu","year":"2020","unstructured":"Hu DG, Mackenzie PI, Nair PC, McKinnon RA, Meech R. The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes. Cancers (Basel). 2020;12(11):3369. https:\/\/doi.org\/10.3390\/cancers12113369.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"409_CR27","doi-asserted-by":"publisher","first-page":"BSR20211433","DOI":"10.1042\/BSR20211433","volume":"41","author":"K Han","year":"2021","unstructured":"Han K, Wang J, Qian K, Zhao T, Zhang Y. Establishment of non-small-cell lung cancer risk prediction model based on prognosis-associated ADME genes. Biosci Rep. 2021;41(10):BSR20211433. https:\/\/doi.org\/10.1042\/BSR20211433.","journal-title":"Biosci Rep."},{"key":"409_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.905635","volume":"13","author":"X Tang","year":"2022","unstructured":"Tang X, Li R, Wu D, Wang Y, Zhao F, Lv R, Wen X. Development and Validation of an ADME-Related Gene Signature for Survival, Treatment Outcome and Immune Cell Infiltration in Head and Neck Squamous Cell Carcinoma. Front Immunol. 2022;13: 905635. https:\/\/doi.org\/10.3389\/fimmu.2022.905635.","journal-title":"Front Immunol"},{"issue":"6","key":"409_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, Zhu J, Haussler D. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0546-8.","journal-title":"Nat Biotechnol"},{"key":"409_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-4598-9-3","volume":"9","author":"WJ Kim","year":"2010","unstructured":"Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3. https:\/\/doi.org\/10.1186\/1476-4598-9-3.","journal-title":"Mol Cancer"},{"issue":"1","key":"409_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s40001-024-01982-6","volume":"29","author":"F Zheng","year":"2024","unstructured":"Zheng F, Wang Z, Li S, Xiong S, Yuan Y, Zeng J, Tan Y, Liu X, Xu S, Fu B. Development of a propionate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis in bladder cancer. Eur J Med Res. 2024;29(1):393. https:\/\/doi.org\/10.1186\/s40001-024-01982-6.","journal-title":"Eur J Med Res"},{"key":"409_CR32","doi-asserted-by":"publisher","first-page":"1430583","DOI":"10.3389\/fimmu.2024.1430583","volume":"15","author":"C Shen","year":"2025","unstructured":"Shen C, Suo Y, Guo J, Su W, Zhang Z, Yang S, Wu Z, Fan Z, Zhou X, Hu H. Development and validation of a glycolysis-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer. Front Immunol. 2025;15:1430583. https:\/\/doi.org\/10.3389\/fimmu.2024.1430583.","journal-title":"Front Immunol"},{"issue":"1","key":"409_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12894-023-01354-y","volume":"24","author":"J Ma","year":"2024","unstructured":"Ma J, Hu J, Zhao L, Wu Z, Li R, Deng W. Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment. BMC Urol. 2024;24(1):6. https:\/\/doi.org\/10.1186\/s12894-023-01354-y.","journal-title":"BMC Urol"},{"issue":"1","key":"409_CR34","doi-asserted-by":"publisher","first-page":"19142","DOI":"10.1038\/s41598-024-70184-1","volume":"14","author":"H Liu","year":"2024","unstructured":"Liu H, Dong A, Rasteh AM, Wang P, Weng J. Identification of the novel exhausted T cell CD8 + markers in breast cancer. Sci Rep. 2024;14(1):19142. https:\/\/doi.org\/10.1038\/s41598-024-70184-1.","journal-title":"Sci Rep"},{"issue":"4","key":"409_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","volume":"16","author":"R Tibshirani","year":"1997","unstructured":"Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385\u201395.","journal-title":"Stat Med"},{"issue":"5","key":"409_CR36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10142-024-01443-7","volume":"24","author":"H Liu","year":"2024","unstructured":"Liu H, Weng J, Huang CL, Jackson AP. Is the voltage-gated sodium channel \u03b23 subunit (SCN3B) a biomarker for glioma? Funct Integr Genomics. 2024;24(5):162. https:\/\/doi.org\/10.1007\/s10142-024-01443-7.","journal-title":"Funct Integr Genomics"},{"issue":"1","key":"409_CR37","doi-asserted-by":"publisher","first-page":"19055","DOI":"10.1038\/s41598-023-45774-0","volume":"13","author":"H Liu","year":"2023","unstructured":"Liu H, Tang T. MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification. Sci Rep. 2023;13(1):19055. https:\/\/doi.org\/10.1038\/s41598-023-45774-0.","journal-title":"Sci Rep"},{"key":"409_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2022.146325","volume":"822","author":"H Liu","year":"2022","unstructured":"Liu H, Weng J. A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma. Gene. 2022;822: 146325. https:\/\/doi.org\/10.1016\/j.gene.2022.146325.","journal-title":"Gene"},{"key":"409_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.858756","volume":"12","author":"H Liu","year":"2022","unstructured":"Liu H, Weng J. A Pan-Cancer Bioinformatic Analysis of RAD51 Regarding the Values for Diagnosis, Prognosis, and Therapeutic Prediction. Front Oncol. 2022;12: 858756. https:\/\/doi.org\/10.3389\/fonc.2022.858756.","journal-title":"Front Oncol"},{"issue":"3","key":"409_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3233\/CBM-210340","volume":"34","author":"Y Li","year":"2022","unstructured":"Li Y, Liu H. Clinical powers of Aminoacyl tRNA Synthetase Complex Interacting Multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma. Cancer Biomark. 2022;34(3):359\u201374. https:\/\/doi.org\/10.3233\/CBM-210340.","journal-title":"Cancer Biomark"},{"issue":"4","key":"409_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3233\/CBM-220143","volume":"35","author":"H Liu","year":"2022","unstructured":"Liu H, Li Y. Potential roles of Cornichon Family AMPA Receptor Auxiliary Protein 4 (CNIH4) in head and neck squamous cell carcinoma. Cancer Biomark. 2022;35(4):439\u201350. https:\/\/doi.org\/10.3233\/CBM-220143.","journal-title":"Cancer Biomark"},{"issue":"5","key":"409_CR42","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"issue":"5","key":"409_CR43","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404\u201323. https:\/\/doi.org\/10.3322\/caac.21631.","journal-title":"CA Cancer J Clin"},{"key":"409_CR44","doi-asserted-by":"publisher","first-page":"1080947","DOI":"10.3389\/fimmu.2022.1080947","volume":"13","author":"B An","year":"2022","unstructured":"An B, Guo Z, Wang J, Zhang C, Zhang G, Yan L. Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma. Front Immunol. 2022;13:1080947. https:\/\/doi.org\/10.3389\/fimmu.2022.1080947.","journal-title":"Front Immunol"},{"issue":"3","key":"409_CR45","first-page":"2140","volume":"15","author":"H Liu","year":"2023","unstructured":"Liu H, Tang T. A bioinformatic study of IGFBPs in glioma regarding their diagnostic, prognostic, and therapeutic prediction value. Am J Transl Res. 2023;15(3):2140\u201355.","journal-title":"Am J Transl Res"},{"key":"409_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108302","volume":"240","author":"H Liu","year":"2022","unstructured":"Liu H, Dilger JP, Lin J. A pan-cancer-bioinformatic-based literature review of TRPM7 in cancers. Pharmacol Ther. 2022;240: 108302. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108302.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"409_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0314745","volume":"20","author":"H Liu","year":"2025","unstructured":"Liu H, Karsidag M, Chhatwal K, Wang P, Tang T. Single-cell and bulk RNA sequencing analysis reveals CENPA as a potential biomarker and therapeutic target in cancers. PLoS ONE. 2025;20(1): e0314745. https:\/\/doi.org\/10.1371\/journal.pone.0314745.","journal-title":"PLoS ONE"},{"issue":"1","key":"409_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40364-024-00620-x","volume":"12","author":"H Liu","year":"2024","unstructured":"Liu H, Weng J, Huang CL, Jackson AP. Voltage-gated sodium channels in cancers. Biomark Res. 2024;12(1):70. https:\/\/doi.org\/10.1186\/s40364-024-00620-x.","journal-title":"Biomark Res"},{"key":"409_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cancergen.2023.10.001","volume":"278\u2013279","author":"H Liu","year":"2023","unstructured":"Liu H, Tang T. Pan-cancer genetic analysis of disulfidptosis-related gene set. Cancer Genet. 2023;278\u2013279:91\u2013103. https:\/\/doi.org\/10.1016\/j.cancergen.2023.10.001.","journal-title":"Cancer Genet"},{"key":"409_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.989030","volume":"13","author":"W Qu","year":"2022","unstructured":"Qu W, Zhang F, Cheng Y, Li J, Zhou J. The impact of genetic variants in the CYP2C8 gene on bladder cancer susceptibility. Front Endocrinol (Lausanne). 2022;13: 989030. https:\/\/doi.org\/10.3389\/fendo.2022.989030.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"409_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.810272","volume":"10","author":"X Song","year":"2022","unstructured":"Song X, Xin S, Zhang Y, Mao J, Duan C, Cui K, Chen L, Li F, Liu Z, Wang T, Liu J, Liu X, Song W. Identification and Quantification of Iron Metabolism Landscape on Therapy and Prognosis in Bladder Cancer. Front Cell Dev Biol. 2022;10: 810272. https:\/\/doi.org\/10.3389\/fcell.2022.810272.","journal-title":"Front Cell Dev Biol"},{"issue":"17","key":"409_CR52","doi-asserted-by":"publisher","first-page":"8847","DOI":"10.1158\/0008-5472.CAN-06-0769","volume":"66","author":"S Zhang","year":"2006","unstructured":"Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006;66(17):8847\u201357. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0769.","journal-title":"Cancer Res"},{"issue":"8","key":"409_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29551","volume":"10","author":"Q Chen","year":"2024","unstructured":"Chen Q, Zhou Q. Identification of exosome-related gene signature as a promising diagnostic and therapeutic tool for breast cancer. Heliyon. 2024;10(8): e29551. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e29551.","journal-title":"Heliyon"},{"issue":"24","key":"409_CR54","doi-asserted-by":"publisher","first-page":"9556","DOI":"10.3390\/ijms21249556","volume":"21","author":"V Hlav\u00e1\u010d","year":"2020","unstructured":"Hlav\u00e1\u010d V, V\u00e1clav\u00edkov\u00e1 R, Brynychov\u00e1 V, Ko\u017eevnikovov\u00e1 R, Kope\u010dkov\u00e1 K, Vr\u00e1na D, Gat\u011bk J, Sou\u010dek P. Role of Genetic Variation in ABC Transporters in Breast Cancer Prognosis and Therapy Response. Int J Mol Sci. 2020;21(24):9556. https:\/\/doi.org\/10.3390\/ijms21249556.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"409_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1021\/cb2004466","volume":"7","author":"SM Muthana","year":"2012","unstructured":"Muthana SM, Campbell CT, Gildersleeve JC. Modifications of glycans: biological significance and therapeutic opportunities. ACS Chem Biol. 2012;7(1):31\u201343. https:\/\/doi.org\/10.1021\/cb2004466.","journal-title":"ACS Chem Biol"},{"key":"409_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108862","volume":"214","author":"XD Hao","year":"2022","unstructured":"Hao XD, Liu YN, Hu SH, Pan XJ, Chen P. Association of macular corneal dystrophy with excessive cell senescence and apoptosis induced by the novel mutant CHST6. Exp Eye Res. 2022;214: 108862. https:\/\/doi.org\/10.1016\/j.exer.2021.108862.","journal-title":"Exp Eye Res"},{"issue":"3","key":"409_CR57","doi-asserted-by":"publisher","first-page":"146","DOI":"10.21037\/atm-22-6502","volume":"11","author":"G Liu","year":"2023","unstructured":"Liu G, Lu Y, Gao D, Huang Z, Ma L. Identification of an energy metabolism-related six-gene signature for distinguishing and forecasting the prognosis of low-grade gliomas. Ann Transl Med. 2023;11(3):146. https:\/\/doi.org\/10.21037\/atm-22-6502.","journal-title":"Ann Transl Med."},{"issue":"18","key":"409_CR58","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1042\/BCJ20240172","volume":"481","author":"T Sato","year":"2024","unstructured":"Sato T, Shizu R, Baba R, Ooka A, Hosaka T, Kanno Y, Yoshinari K. Pregnane X receptor inhibits the transdifferentiation of hepatic stellate cells by down-regulating periostin expression. Biochem J. 2024;481(18):1173\u201386. https:\/\/doi.org\/10.1042\/BCJ20240172.","journal-title":"Biochem J"},{"key":"409_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03598-y","author":"L Dong","year":"2024","unstructured":"Dong L, Dong C, Yu Y, Jiao X, Zhang X, Zhang X, Li Z. Transcriptomic analysis of Paraoxonase 1 expression in hepatocellular carcinoma and its potential impact on tumor immunity. Clin Transl Oncol. 2024. https:\/\/doi.org\/10.1007\/s12094-024-03598-y.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"409_CR60","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12885-022-10491-w","volume":"23","author":"Z Tu","year":"2023","unstructured":"Tu Z, Li K, Ji Q, Huang Y, Lv S, Li J, Wu L, Huang K, Zhu X. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy. BMC Cancer. 2023;23(1):133. https:\/\/doi.org\/10.1186\/s12885-022-10491-w.","journal-title":"BMC Cancer"},{"issue":"2","key":"409_CR61","first-page":"2702","volume":"8","author":"X Che","year":"2015","unstructured":"Che X, Yu D, Wu Z, Zhang J, Chen Y, Han Y, Wang C, Qi J. Polymorphisms in UGT2B4 and susceptibility to pancreatic cancer. Int J Clin Exp Med. 2015;8(2):2702\u201310.","journal-title":"Int J Clin Exp Med"},{"issue":"16","key":"409_CR62","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3760\/cma.j.issn.0376-2491.2018.16.011","volume":"98","author":"QL Gao","year":"2018","unstructured":"Gao QL, Zhang XF, Geng L, Tian TD, Sun XF. Effect of single nucleotide polymorphisms of RS1826690 located in UGT2B4 gene on the pathological complete response to neoadjuvant chemotherapy in breast cancer patients. Zhonghua Yi Xue Za Zhi. 2018;98(16):1242\u20135. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2018.16.011. Chinese.","journal-title":"Zhonghua Yi Xue Za Zhi."},{"issue":"6","key":"409_CR63","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.21037\/jgo-23-895","volume":"14","author":"L Jin","year":"2023","unstructured":"Jin L, Huang J, Guo L, Zhang B, Li Q, Li H, Yu M, Xie P, Yu Q, Chen Z, Liu S, Xu Y, Xiao Y, Lu M, Ye Q. CYP1B1 promotes colorectal cancer liver metastasis by enhancing the growth of metastatic cancer cells via a fatty acids-dependent manner. J Gastrointest Oncol. 2023;14(6):2448\u201365. https:\/\/doi.org\/10.21037\/jgo-23-895.","journal-title":"J Gastrointest Oncol."},{"key":"409_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.561804","volume":"8","author":"X Huo","year":"2020","unstructured":"Huo X, Sun H, Qian Q, Ma X, Peng P, Yu M, Zhang Y, Yang J, Cao D, Gui T, Shen K. CYP27B1 Downregulation: A New Molecular Mechanism Regulating EZH2 in Ovarian Cancer Tumorigenicity. Front Cell Dev Biol. 2020;8: 561804. https:\/\/doi.org\/10.3389\/fcell.2020.561804.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"409_CR65","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.11817\/j.issn.1672-7347.2023.230150","volume":"48","author":"Q Jia","year":"2023","unstructured":"Jia Q, Ding Q, Shao K, Dang J, Zhang F. Research progress regarding CYP3A gene family in gastric cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023;48(12):1874\u201381. https:\/\/doi.org\/10.11817\/j.issn.1672-7347.2023.230150. English, Chinese.","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban."},{"issue":"10","key":"409_CR66","doi-asserted-by":"publisher","first-page":"101042831771927","DOI":"10.1177\/1010428317719272","volume":"39","author":"J Zou","year":"2017","unstructured":"Zou J, Li H, Huang Q, Liu X, Qi X, Wang Y, Lu L, Liu Z. Dopamine-induced SULT1A3\/4 promotes EMT and cancer stemness in hepatocellular carcinoma. Tumour Biol. 2017;39(10):1010428317719272. https:\/\/doi.org\/10.1177\/1010428317719272.","journal-title":"Tumour Biol"},{"issue":"10","key":"409_CR67","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.3390\/ijms19103028","volume":"19","author":"C Walker","year":"2018","unstructured":"Walker C, Mojares E, Del R\u00edo HA. Role of Extracellular Matrix in Development and Cancer Progression. Int J Mol Sci. 2018;19(10):3028. https:\/\/doi.org\/10.3390\/ijms19103028.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"409_CR68","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nrc3726","volume":"14","author":"DM Gilkes","year":"2014","unstructured":"Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430\u20139. https:\/\/doi.org\/10.1038\/nrc3726.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"409_CR69","doi-asserted-by":"publisher","first-page":"21138","DOI":"10.3390\/ijms160921138","volume":"16","author":"S Faes","year":"2015","unstructured":"Faes S, Dormond O. PI3K and AKT: Unfaithful Partners in Cancer. Int J Mol Sci. 2015;16(9):21138\u201352. https:\/\/doi.org\/10.3390\/ijms160921138.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"409_CR70","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40164-023-00446-7","volume":"12","author":"X Tan","year":"2023","unstructured":"Tan X, Yan Y, Song B, Zhu S, Mei Q, Wu K. Focal adhesion kinase: from biological functions to therapeutic strategies. Exp Hematol Oncol. 2023;12(1):83. https:\/\/doi.org\/10.1186\/s40164-023-00446-7.","journal-title":"Exp Hematol Oncol"},{"issue":"13","key":"409_CR71","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1158\/1078-0432.CCR-17-2687","volume":"24","author":"H Fu","year":"2018","unstructured":"Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H, Fu Q, Dai B, Ye D, Xu J. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2018;24(13):3069\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2687.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"409_CR72","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.juro.2008.11.090","volume":"181","author":"H Takayama","year":"2009","unstructured":"Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol. 2009;181(4):1894\u2013900. https:\/\/doi.org\/10.1016\/j.juro.2008.11.090.","journal-title":"J Urol"},{"issue":"7","key":"409_CR73","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1046\/j.1442-2042.2000.00190.x","volume":"7","author":"T Hanada","year":"2000","unstructured":"Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol. 2000;7(7):263\u20139. https:\/\/doi.org\/10.1046\/j.1442-2042.2000.00190.x.","journal-title":"Int J Urol"},{"issue":"5","key":"409_CR74","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.3892\/ol.2016.4392","volume":"11","author":"H Takeuchi","year":"2016","unstructured":"Takeuchi H, Tanaka M, Tanaka A, Tsunemi A, Yamamoto H. Predominance of M2-polarized macrophages in bladder cancer affects angiogenesis, tumor grade and invasiveness. Oncol Lett. 2016;11(5):3403\u20138. https:\/\/doi.org\/10.3892\/ol.2016.4392.","journal-title":"Oncol Lett"},{"issue":"6","key":"409_CR75","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1442-2042.2006.01697.x","volume":"14","author":"M Naoe","year":"2007","unstructured":"Naoe M, Ogawa Y, Takeshita K, Morita J, Iwamoto S, Miyazaki A, Yoshida H. Bacillus Calmette-Gu\u00e9rin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells. Int J Urol. 2007;14(6):532\u20138. https:\/\/doi.org\/10.1111\/j.1442-2042.2006.01697.x. discussion 538.","journal-title":"Int J Urol."},{"key":"409_CR76","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3389\/fonc.2019.01270","volume":"9","author":"M Joseph","year":"2019","unstructured":"Joseph M, Enting D. Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications. Front Oncol. 2019;9:1270. https:\/\/doi.org\/10.3389\/fonc.2019.01270.","journal-title":"Front Oncol"},{"issue":"1","key":"409_CR77","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2011.06.054","volume":"219","author":"M Rosenblat","year":"2011","unstructured":"Rosenblat M, Volkova N, Ward J, Aviram M. Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation. Atherosclerosis. 2011;219(1):49\u201356. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.06.054.","journal-title":"Atherosclerosis"},{"issue":"7","key":"409_CR78","doi-asserted-by":"publisher","first-page":"e6385","DOI":"10.1371\/journal.pone.0006385","volume":"4","author":"XL Li","year":"2009","unstructured":"Li XL, Liu YY, Knight D, Odaka Y, Mathis JM, Shi R, Glass J, Zhang QJ. Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expression. PLoS One. 2009;4(7):e6385. https:\/\/doi.org\/10.1371\/journal.pone.0006385.","journal-title":"PLoS One."},{"issue":"7","key":"409_CR79","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/s0092-8674(05)80068-6","volume":"71","author":"L Van Kaer","year":"1992","unstructured":"Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell. 1992;71(7):1205\u201314. https:\/\/doi.org\/10.1016\/s0092-8674(05)80068-6.","journal-title":"Cell"},{"issue":"5","key":"409_CR80","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","volume":"19","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19(5):1035\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2064.","journal-title":"Clin Cancer Res"},{"issue":"6024","key":"409_CR81","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O\u2019Dwyer PJ, Vonderheide RH. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612\u20136. https:\/\/doi.org\/10.1126\/science.1198443.","journal-title":"Science"},{"issue":"3","key":"409_CR82","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.3892\/mmr.2018.9306","volume":"18","author":"YD Zhu","year":"2018","unstructured":"Zhu YD, Lu MY. Increased expression of TNFRSF14 indicates good prognosis and inhibits bladder cancer proliferation by promoting apoptosis. Mol Med Rep. 2018;18(3):3403\u201310. https:\/\/doi.org\/10.3892\/mmr.2018.9306.","journal-title":"Mol Med Rep"},{"issue":"9","key":"409_CR83","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/eji.201141477","volume":"41","author":"TJ Slebioda","year":"2011","unstructured":"Slebioda TJ, Rowley TF, Ferdinand JR, Willoughby JE, Buchan SL, Taraban VY, Al-Shamkhani A. Triggering of TNFRSF25 promotes CD8\u207a T-cell responses and anti-tumor immunity. Eur J Immunol. 2011;41(9):2606\u201311. https:\/\/doi.org\/10.1002\/eji.201141477.","journal-title":"Eur J Immunol"},{"key":"409_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024","volume":"132","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Liu Z, Deng K, Qu H, Zhang Q, Zhou P, Yang M, Yang X, Wang H, Li R, Xia J. Identification of TAP1 as a T-cell related therapeutic target in gastric cancer by mediating oxalipliatin-related synergistic enhancement of immunotherapy. Int Immunopharmacol. 2024;132: 111998. https:\/\/doi.org\/10.1016\/j.intimp.2024.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"409_CR85","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41419-023-05803-2","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen C, Yang Y, Guo Y, He J, Chen Z, Qiu S, Zhang Y, Ding H, Pan J, Pan Y. CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer. Cell Death Dis. 2023;14(4):271. https:\/\/doi.org\/10.1038\/s41419-023-05803-2.","journal-title":"Cell Death Dis"},{"issue":"17","key":"409_CR86","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-16-0903","volume":"22","author":"RM Chabanon","year":"2016","unstructured":"Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria JC, Postel-Vinay S. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clin Cancer Res. 2016;22(17):4309\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0903.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"409_CR87","doi-asserted-by":"publisher","first-page":"9670","DOI":"10.3390\/ijms23179670","volume":"23","author":"PR Hollis","year":"2022","unstructured":"Hollis PR, Mobley RJ, Bhuju J, Abell AN, Sutter CH, Sutter TR. CYP1B1 Augments the Mesenchymal, Claudin-Low, and Chemoresistant Phenotypes of Triple-Negative Breast Cancer Cells. Int J Mol Sci. 2022;23(17):9670. https:\/\/doi.org\/10.3390\/ijms23179670.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"409_CR88","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1124\/jpet.106.110346","volume":"319","author":"A Yonezawa","year":"2006","unstructured":"Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319(2):879\u201386. https:\/\/doi.org\/10.1124\/jpet.106.110346.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"409_CR89","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1124\/dmd.108.023168","volume":"36","author":"S Yokoo","year":"2008","unstructured":"Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos. 2008;36(11):2299\u2013306. https:\/\/doi.org\/10.1124\/dmd.108.023168.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"409_CR90","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1124\/dmd.114.057695","volume":"42","author":"AM Filppula","year":"2014","unstructured":"Filppula AM, Neuvonen PJ, Backman JT. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014;42(7):1202\u20139. https:\/\/doi.org\/10.1124\/dmd.114.057695.","journal-title":"Drug Metab Dispos"},{"key":"409_CR91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-030-60204-8_1","volume":"1299","author":"K Okumoto","year":"2020","unstructured":"Okumoto K, Tamura S, Honsho M, Fujiki Y. Peroxisome: Metabolic Functions and Biogenesis. Adv Exp Med Biol. 2020;1299:3\u201317. https:\/\/doi.org\/10.1007\/978-3-030-60204-8_1.","journal-title":"Adv Exp Med Biol"},{"issue":"22","key":"409_CR92","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1007\/s00018-020-03536-5","volume":"77","author":"A Kirtonia","year":"2020","unstructured":"Kirtonia A, Sethi G, Garg M. The multifaceted role of reactive oxygen species in tumorigenesis. Cell Mol Life Sci. 2020;77(22):4459\u201383. https:\/\/doi.org\/10.1007\/s00018-020-03536-5.","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"409_CR93","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.3390\/biomedicines12122750","volume":"12","author":"G Molla","year":"2024","unstructured":"Molla G, Bitew M. Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. Biomedicines. 2024;12(12):2750. https:\/\/doi.org\/10.3390\/biomedicines12122750.","journal-title":"Biomedicines"},{"issue":"3","key":"409_CR94","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.eururo.2009.11.036","volume":"57","author":"DJ DeGraff","year":"2010","unstructured":"DeGraff DJ. Novel use of a combined artificial intelligence approach to identify patients with noninvasive urothelial cell carcinoma of the urinary bladder who are at greatest risk for progression to muscle-invasive disease: a step forward. Eur Urol. 2010;57(3):407\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2009.11.036. discussion 408\u20139.","journal-title":"Eur Urol."},{"issue":"1","key":"409_CR95","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40200-021-00824-0","volume":"21","author":"F Khatami","year":"2021","unstructured":"Khatami F, Hassanzad M, Nikfar S, Guitynavard F, Karimaee S, Tamehri Zadeh SS, Gholami K, Rezaeian A, Feiz-Abadi SA, Jahanshahi F, Aghamir SMK. The importance of personalized medicine in urological cancers. J Diabetes Metab Disord. 2021;21(1):841\u201352. https:\/\/doi.org\/10.1007\/s40200-021-00824-0.","journal-title":"J Diabetes Metab Disord"},{"issue":"3","key":"409_CR96","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.annonc.2022.01.073","volume":"33","author":"AA D'souza","year":"2022","unstructured":"D\u2019souza AA, Tulpule V, Zang PD, Quinn DI. Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape. Ann Oncol. 2022;33(3):242\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.073.","journal-title":"Ann Oncol"},{"issue":"10","key":"409_CR97","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3390\/cells11101614","volume":"11","author":"M Audisio","year":"2022","unstructured":"Audisio M, Buttigliero C, Turco F, Delcuratolo MD, Pisano C, Parlagreco E, Di Stefano RF, Di Prima L, Crespi V, Farinea G, Cani M, Tucci M. Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine? Cells. 2022;11(10):1614. https:\/\/doi.org\/10.3390\/cells11101614.","journal-title":"Cells"},{"issue":"1","key":"409_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35670","volume":"131","author":"CD Bergerot","year":"2025","unstructured":"Bergerot CD, Schmitz KH, Crane TE, Klaassen Z, Bergerot PG. Comprehensive care for patients with bladder cancer: Addressing the interplay of physical, nutritional, and emotional well-being. Cancer. 2025;131(1): e35670. https:\/\/doi.org\/10.1002\/cncr.35670.","journal-title":"Cancer"},{"issue":"6","key":"409_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2024.10181","volume":"15","author":"VC Rutten","year":"2024","unstructured":"Rutten VC, Al CM, Festen S, Zuiverloon TCM, Boormans JL, Polinder-Bos HA. Selecting the right treatment: Health outcome priorities in older patients with bladder cancer. J Geriatr Oncol. 2024;15(6): 101811. https:\/\/doi.org\/10.1016\/j.jgo.2024.10181.","journal-title":"J Geriatr Oncol"},{"key":"409_CR100","doi-asserted-by":"publisher","unstructured":"Liu H, Guo Z, Wang P. Genetic expression in cancer research: Challenges and complexity. Gene Reports. 2024: 102042. https:\/\/doi.org\/10.1016\/j.genrep.2024.102042.","DOI":"10.1016\/j.genrep.2024.102042"},{"issue":"1","key":"409_CR101","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7150\/jca.100922","volume":"16","author":"H Liu","year":"2025","unstructured":"Liu H, Li Y, Karsidag M, Tu T, Wang P. Technical and Biological Biases in Bulk Transcriptomic Data Mining for Cancer Research. J Cancer. 2025;16(1):34\u201343. https:\/\/doi.org\/10.7150\/jca.100922.","journal-title":"J Cancer"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00409-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00409-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00409-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:02:12Z","timestamp":1742371332000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-025-00409-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00409-4","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}